Dry eye disease (DED) is a common ocular condition affecting 5% to 50% of the global population, characterized by tear film instability and hyperosmolarity, ocular surface inflammation, and neurosensory abnormalities. Conventional treatments, such as artificial tears, cyclosporin, corticosteroids, mucin secretagogues, and nonsteroidal anti-inflammatory drugs, have limitations including low bioavailability, rapid drug metabolism, and frequent administration requirements. Nanomedicine offers promising solutions to address these issues, with various nanotherapeutics like nano-emulsions, nanosuspensions, liposomes, and micelles showing significant potential. Some of these nanoformulations have already received FDA approval for DED treatment. This article provides an overview of the latest advancements in nanomedicine for DED management, highlighting the benefits of enhanced bioavailability, targeted delivery, lower dosage, reduced side effects, and improved patient compliance. The field of DED treatment is expected to witness significant breakthroughs with the development of nanomedicine, offering hope for improved outcomes for patients worldwide.Dry eye disease (DED) is a common ocular condition affecting 5% to 50% of the global population, characterized by tear film instability and hyperosmolarity, ocular surface inflammation, and neurosensory abnormalities. Conventional treatments, such as artificial tears, cyclosporin, corticosteroids, mucin secretagogues, and nonsteroidal anti-inflammatory drugs, have limitations including low bioavailability, rapid drug metabolism, and frequent administration requirements. Nanomedicine offers promising solutions to address these issues, with various nanotherapeutics like nano-emulsions, nanosuspensions, liposomes, and micelles showing significant potential. Some of these nanoformulations have already received FDA approval for DED treatment. This article provides an overview of the latest advancements in nanomedicine for DED management, highlighting the benefits of enhanced bioavailability, targeted delivery, lower dosage, reduced side effects, and improved patient compliance. The field of DED treatment is expected to witness significant breakthroughs with the development of nanomedicine, offering hope for improved outcomes for patients worldwide.